340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

340: Crisis in CRISPR world, RFK Jr.'s promis...

Suivant

393: A conversation with the 'godfather' of biotech

On this week's episode of "The Readout LOUD," we bring you a special conversation with Stelios Papadapolous, also know as the "godfather" of biotech. He sat down for an on-stage chat with our colleague Damian Garde Thursday afternoon during STAT’s Breakthrough Summit East event i ...  Afficher plus

392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA

How was a known friend of Jeffrey Epstein able to raise $100 million, with the help of a prominent biotech VC? And will Vinay Prasad return to the Food and Drug Administration for a "three-peat"? Damian Garde joins Allison, Adam, and Elaine to discuss his article about Boris Niko ...  Afficher plus

Épisodes Recommandés

Eli Lilly CEO: The Weight-Loss Drug Revolution, AI in Pharma, and Innovation
In Good Company with Nicolai Tangen

Nicolai Tangen meets with David Ricks, CEO of Eli Lilly, for a discussion about the pharmaceutical giant's remarkable journey. At the forefront is Eli Lilly's breakthrough work with weight reduction drugs, which are showing promise far beyond their original ...

  Afficher plus

Market Surge, Treatment Hopes, Retail Sales, Royalty Pharma CEO, SoftBank’s T-Mobile Stake
Squawk on the Street

David Faber and Jim Cramer discuss the massive surge for stocks. Multiple reports emerging saying dexamethasone, a widely available drug, can help critically ill coronavirus patients. The treatment reportedly reduced Covid-19 deaths in hospitalized patients by up to one third. ...

  Afficher plus

Finally, a resolution to the Purdue Pharma case?
Make Me Smart

Purdue Pharma’s owners in the Sackler family have agreed to a new $6.5 billion settlement to lawsuits over their role in the U.S. opioid crisis. This comes after a previous deal was rejected by the Supreme Court last year. We’ll break down the details of the settlement and wha ...

  Afficher plus

Market Rally Aims for “Cloud Nine,” Bronfman's Paramount Bid, Eli Lilly CEO on Weight-Loss Drug 8/20/24
Squawk on the Street

Carl Quintanilla and Jim Cramer led off the show by delving into the broadening market rally, as the S&P 500 and Nasdaq aim for a ninth consecutive day of gains. David Faber called into the show with reporting on Edgar Bronfman's bid to acquire Paramount Global. Eli Lilly CEO ...

  Afficher plus